Your browser doesn't support javascript.
loading
Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
Milliet, Florent; Bozec, Alexandre; Schiappa, Renaud; Viotti, Julien; Modesto, Anouchka; Dassonville, Olivier; Poissonnet, Gilles; Guelfucci, Bruno; Bizeau, Alain; Vergez, Sebastien; Dupret-Bories, Agnes; Garrel, Renaud; Fakhry, Nicolas; Santini, Laure; Lallemant, Benjamin; Chambon, Guillaume; Sudaka, Anne; Peyrade, Frederic; Saada-Bouzid, Esma; Benezery, Karen; Jourdan-Soulier, Florence; Chapel, Françoise; Sophie Ramay, Anne; Roger, Pascal; Galissier, Thibault; Coste, Valérie; Ben Lakdar, Aicha; Guerlain, Joanne; Temam, Stephane; Mirghani, Haitham; Gorphe, Phillipe; Chamorey, Emmanuel; Culié, Dorian.
Afiliação
  • Milliet F; Department of Otorhinolaryngology, University Hospital of Nice, France.
  • Bozec A; University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Schiappa R; Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Viotti J; Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Modesto A; Department of Radiotherapy, Cancer University Institute of Toulouse, Toulouse, France.
  • Dassonville O; University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Poissonnet G; University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Guelfucci B; Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.
  • Bizeau A; Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.
  • Vergez S; Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.
  • Dupret-Bories A; Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.
  • Garrel R; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Montpellier, Montpellier, France.
  • Fakhry N; Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.
  • Santini L; Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.
  • Lallemant B; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.
  • Chambon G; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.
  • Sudaka A; Department of Pathology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Peyrade F; Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Saada-Bouzid E; Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Benezery K; Department of Radiotherapy, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Jourdan-Soulier F; Department of Pathology, Sainte Musse Hospital, Toulon, France.
  • Chapel F; Department of Pathology, Sainte Musse Hospital, Toulon, France.
  • Sophie Ramay A; Department of Pathology, University Hospital of Nîmes, Nîmes, France.
  • Roger P; Department of Pathology, University Hospital of Nîmes, Nîmes, France.
  • Galissier T; Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France.
  • Coste V; Department of Pathology, University Hospital of Montpellier, Montpellier, France.
  • Ben Lakdar A; Department of Pathology, Gustave Roussy Institute, Villejuif, France.
  • Guerlain J; Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.
  • Temam S; Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.
  • Mirghani H; Department of Head and Neck Surgery, European Georges Pompidou Hospital, APHP, Paris, France.
  • Gorphe P; Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.
  • Chamorey E; Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.
  • Culié D; University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France. Electronic address: dorian.culie@nice.unicancer.fr.
Oral Oncol ; 112: 105041, 2021 01.
Article em En | MEDLINE | ID: mdl-33129057
ABSTRACT

INTRODUCTION:

Patients with oropharyngeal squamous cell carcinoma (OPSCC) display a significant risk of synchronous primary neoplasia (SPN) which could impact their management. The aims of this study were to evaluate the risk and distribution of SPN in OPSCC patients according to their HPV (p16) status, the predictive factors of SPN and the impact of SPN on therapeutic strategy and oncologic outcomes. MATERIAL AND

METHODS:

All OPSCC patients treated from 2009 to 2014 were included in this multicentric retrospective study. Univariate analyses were conducted using Chi-2 and Fisher exact tests. For multivariate analyses, all variables associated with a p ≤ 0.10 in univariate analysis were included in logistic regression models.

RESULTS:

Among the 1291 patients included in this study, 75 (5.8%) displayed a SPN which was preferentially located in the upper aerodigestive tract, lung and esophagus. Comorbidity level (p = 0.03), alcohol (p = 0.005) and tobacco (p = 0.01) consumptions, and p16 tumor status (p < 0.0001) were significant predictors of SPN. In multivariate analysis, p16+ status was significantly associated with a lower risk of SPN (OR = 0.251, IC95% [0.133;0.474]). Patients with a SPN were more frequently referred for non-curative treatment (p = 0.02). In patients treated with curative intent, there was no impact of SPN on the therapeutic strategy (surgical vs. non-surgical treatment). We observed no overall survival differences between patients with or without SPN.

CONCLUSION:

P16 tumor status is the main predictive factor of SPN in OPSCC patients. This study provides crucial results which should help adapt the initial work-up and the global management of OPSCC patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Orofaríngeas / Papillomavirus Humano 16 / Carcinoma de Células Escamosas de Cabeça e Pescoço / Neoplasias Primárias Múltiplas Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Orofaríngeas / Papillomavirus Humano 16 / Carcinoma de Células Escamosas de Cabeça e Pescoço / Neoplasias Primárias Múltiplas Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article